Safety concerns associated with the use of OCS, including amniotic fluid embolism, sepsis, hemolysis, coagulopathy, and Rh alloimmunization, have been substantially addressed through advancements in technology, the implementation of leukocyte depletion filters, and the routine administration of anti-D prophylaxis. The gene discussed is RHD; the disease is amniotic fluid embolism.